Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Check-Cap Ltd. (CHEK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9000-0.9400 (-24.48%)
At close: 04:00PM EST
3.0000 +0.10 (+3.45%)
After hours: 05:54PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close3.8400
Open3.8000
Bid2.9500 x 800
Ask3.3500 x 900
Day's Range2.9000 - 4.3800
52 Week Range2.9000 - 17.8000
Volume409,797
Avg. Volume32,883
Market Cap16.891M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)-0.2130
Earnings DateNov 30, 2022 - Dec 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CHEK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Check-Cap Ltd.
    Analyst Report: Quest Diagnostics, Inc.Quest Diagnostics is a provider of clinical diagnostic services that help to identify and treat disease and improve healthcare management. Quest is based in Secaucus, New Jersey; the stock is a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    19 days agoArgus Research
View more
  • PR Newswire

    Check-Cap Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the second quarter and six months ended June 30, 2022.

  • PR Newswire

    Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), announces that on June 22, 2022, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is eligible for an additional 180 calendar day period, or until Dec

  • Simply Wall St.

    We're Hopeful That Check-Cap (NASDAQ:CHEK) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Advertisement
Advertisement